Evans syndrome and Systemic Lupus Erythematosus: Clinical presentation and outcome

dc.creatorCostallat, GL
dc.creatorAppenzeller, S
dc.creatorCostallat, LTL
dc.date2012
dc.dateJUL
dc.date2014-07-30T17:29:45Z
dc.date2015-11-26T16:47:42Z
dc.date2014-07-30T17:29:45Z
dc.date2015-11-26T16:47:42Z
dc.date.accessioned2018-03-28T23:33:53Z
dc.date.available2018-03-28T23:33:53Z
dc.identifierJoint Bone Spine. Elsevier France-editions Scientifiques Medicales Elsevier, v. 79, n. 4, n. 362, n. 364, 2012.
dc.identifier1297-319X
dc.identifierWOS:000306089000007
dc.identifier10.1016/j.jbspin.2011.07.004
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/66043
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/66043
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1274930
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionObjective: To review the clinical, laboratory and outcome features of Evans syndrome (ES) in systemic lupus erythematosus (SLE) patients. Methods: We reviewed the charts of 953 SLE patients followed up regularly at our service. ES was defined as the presence of hemolytic anemia and thrombocytopenia concomitantly or sequentially. Clinical and laboratory manifestations occurring during the disease course, as well as concomitant diseases and survival was carefully reviewed. Results: We identified ES in 26 of 953 (2.7%) SLE patients. Twenty-three were women with mean age at SLE diagnosis of 25.7 years. Four (15%) patients had disease onset before the age of 16. In the majority of patients (92%), immune thrombocytopenia and AIHA appeared simultaneously at the beginning of SLE. Active features of SLE were a frequent finding concomitant to ES, especially arthritis (77%), malar rash (61.5%), photosensitivity (57.6%), oral ulcers (34.6%), nephritis (73%), serositis (54%), neuropsychiatric (19%) and pulmonary (15%) manifestations. In addition to this multisystemic disease, 34.6% of our patients had an association with another autoimmune disease such as antiphospholipid syndrome. Recurrence of ES was observed in only four (15%) patients. After follow-up time of 8.72 years, 19 patients (73%) were in remission and seven (27%) patients died. Discussion: ES is a rare manifestation in SLE, occurring in patients with severe multisystemic SLE manifestations. Treatment strategies frequently used in SLE contribute to longer disease remission and less frequent exacerbation than observed in the general population with ES. (C) 2011 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.
dc.description79
dc.description4
dc.description362
dc.description364
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionFAPESP [FAPESP 08/020917-0, 09/11076-2]
dc.descriptionCNPq [301112-2007-, 0300447/2009-4]
dc.languageen
dc.publisherElsevier France-editions Scientifiques Medicales Elsevier
dc.publisherParis
dc.publisherFrança
dc.relationJoint Bone Spine
dc.relationJoint Bone Spine
dc.rightsfechado
dc.rightshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.sourceWeb of Science
dc.subjectHemolytic anemia
dc.subjectSystemic lupus erythematosus
dc.subjectImmune thrombocytopenia
dc.subjectEvans syndrome
dc.subjectAutoimmune Hemolytic-anemia
dc.subjectThrombocytopenic Purpura
dc.subjectPrevalence
dc.subjectRituximab
dc.subjectDisease
dc.titleEvans syndrome and Systemic Lupus Erythematosus: Clinical presentation and outcome
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución